谷歌浏览器插件
订阅小程序
在清言上使用

Phase II multicenter randomized trial to assess the efficacy and safety of first line nivolumab in combination with paclitaxel in subjects with R/M HNSCC unable for cisplatin-based chemotherapy (NIVOTAX): A TTCC study.

JOURNAL OF CLINICAL ONCOLOGY(2021)

引用 0|浏览37
暂无评分
关键词
paclitaxel,chemotherapy,first line nivolumab,cisplatin-based
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要